To experimentally validate this, we assessed tumor growth and mouse survival in STL mice with CCRT-treated advanced MC38 tumors, exploring the effects of additional treatments with either anti-PD-1 alone, rhIL-7-hyFc alone, or a combination of both. Here, PDCD1 is linked to neoplasm.